AMLX
Bearish signalScored 2026-10-11 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
Research, not advice.
À propos
Amylyx Pharmaceuticals, Inc.
- Nom
- Amylyx Pharmaceuticals, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $3.6B
- Employés
- 136
- PDG
- Joshua Cohen
- Site web
- https://amylyx.com
- Marché
- ACIUAVXLCLNNDNLIELDNIONS
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 90 928 titres (~2 789 282,24 $ US)
- Insiders
- MILNE GEORGE M JRKlee Justin B.Cohen Joshua B
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$1,012,935
Avg sell (VWAP, 90d window) $28.54 vs last close $26.34 (-7.7%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$830,904 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-05
- Liquidity
- Liquid $34,817,950/day · 20d vol
- Last synced
-
2026-10-16 21:10:07
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-05 | MILNE GEORGE M JR | Sell · S S · 10b5-1 | 30,000 | $27.70 | ≈ $830,904 | Form 4 |
| 2026-09-10 | Bedrosian Camille L | Sell · S S | 2,081 | $33.09 | ≈ $68,864 | Form 4 |
| 2026-09-10 | Cohen Joshua B | Sell · S S | 919 | $33.15 | ≈ $30,464 | Form 4 |
| 2026-09-10 | FRATES JAMES M | Sell · S S | 1,042 | $33.23 | ≈ $34,626 | Form 4 |
| 2026-09-10 | Klee Justin B. | Sell · S S | 1,439 | $33.16 | ≈ $47,710 | Form 4 |
| 2026-09-10 | Mazzariello Gina | Sell · S S | 11 | $33.34 | ≈ $367 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2022-10-12 | Chris Jacobs | Purchase | $1,001 - $15,000 |
Signal
Bearish signalScored 2026-10-11 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
AMLX presents a deeply conflicted profile: the Phase III LUCIDITY trial success is a genuine binary catalyst that could set up an FDA filing, but the complete absence of revenue, persistent cash burn, and extreme…
The first sentence of the analysis written for AMLX on 2026-10-11 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 14.27 · operating margin 0.0%
Suggested stop 25.41, nearest stored support minus 0.5 ATR(3.5% under the last close). Reward/risk to the next stored resistance is 8.60. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 51.8% | 93.3% | 86.5% | 0.0% | |
| Ebit Margin | 0.0% | -334.1% | 14.3% | -888.9% | 0.0% | |
| Ebitda Margin | 0.0% | -333.0% | 14.5% | -886.7% | 0.0% | |
| Operating Profit Margin | 0.0% | -360.2% | 10.2% | -905.7% | 0.0% | |
| Pretax Profit Margin | 0.0% | -345.8% | 14.3% | -888.9% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | -345.4% | 12.9% | -892.4% | 0.0% | |
| Net Profit Margin | 0.0% | -345.4% | 12.9% | -892.4% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | -345.4% | 12.9% | -892.4% | 0.0% | |
| Current Ratio | 14.266 | 6.669 | 5.664 | 8.199 | 6.033 | |
| Quick Ratio | 14.266 | 6.669 | 5.197 | 7.989 | 6.033 | |
| Solvency Ratio | -5.266 | -10.421 | 0.599 | -3.892 | -0.342 | |
| Cash Ratio | 9.990 | 2.724 | 2.075 | 1.342 | 2.885 | |
| Price To Earnings Ratio | -7.895 | -0.853 | 20.164 | -12.399 | -11.888 | |
| Price To Earnings Growth Ratio | 0.121 | 0.001 | -0.162 | -0.129 | -0.129 | |
| Forward Price To Earnings Growth Ratio | 0.121 | 0.001 | -0.162 | -0.129 | -0.129 | |
| Price To Earnings Diluted Ratio | -7.895 | -0.853 | 21.029 | -12.399 | -11.888 | |
| Price To Earnings Diluted Growth Ratio | 0.121 | 0.001 | -0.170 | -0.129 | -0.129 | |
| Price To Book Ratio | 3.742 | 1.563 | 2.283 | 7.215 | -6.917 | |
| Price To Sales Ratio | 0.000 | 2.948 | 2.599 | 110.554 | 0.000 | |
| Price To Free Cash Flow Ratio | -9.251 | -1.535 | 92.685 | -13.474 | -13.913 | |
| Price To Operating Cash Flow Ratio | -9.262 | -1.536 | 83.035 | -13.663 | -13.979 | |
| Debt To Assets Ratio | 0.018 | 0.010 | 0.008 | 0.016 | 0.000 | |
| Debt To Equity Ratio | 0.020 | 0.012 | 0.010 | 0.018 | 0.000 | |
| Debt To Capital Ratio | 0.019 | 0.012 | 0.010 | 0.018 | 0.000 | |
| Long Term Debt To Capital Ratio | 0.015 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.090 | 1.175 | 1.194 | 1.149 | -0.699 | |
| Working Capital Turnover Ratio | 0.000 | 0.321 | 1.060 | 0.105 | 0.000 | |
| Operating Cash Flow Ratio | -5.436 | -5.902 | 0.145 | -3.859 | -4.300 | |
| Operating Cash Flow Sales Ratio | 0.000 | -1.919 | 0.031 | -8.091 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | 1.001 | 0.896 | 1.014 | 1.005 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -20.706 | -84.627 | 2.813 | -28.656 | 0.000 | |
| Capital Expenditure Coverage Ratio | -893.790 | -1,067.815 | 9.604 | -71.208 | -211.895 | |
| Dividend Paid And Capex Coverage Ratio | -893.790 | -1,067.815 | 9.604 | -71.208 | -211.895 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -6.393 | -0.626 | 14.873 | -12.183 | -11.327 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | ▼-51.7% | ▼-46.3% |
| Ebit Margin | 0.0% | ▲334.1% | ▲241.7% |
| Ebitda Margin | 0.0% | ▲333.0% | ▲241.0% |
| Operating Profit Margin | 0.0% | ▲360.2% | ▲251.1% |
| Pretax Profit Margin | 0.0% | ▲345.8% | ▲244.1% |
| Continuous Operations Profit Margin | 0.0% | ▲345.4% | ▲245.0% |
| Net Profit Margin | 0.0% | ▲345.4% | ▲245.0% |
| Bottom Line Profit Margin | 0.0% | ▲345.4% | ▲245.0% |
| Current Ratio | 14.266 | ▲7.597 | ▲6.100 |
| Quick Ratio | 14.266 | ▲7.597 | ▲6.235 |
| Solvency Ratio | -5.266 | ▲5.155 | ▼-1.401 |
| Cash Ratio | 9.990 | ▲7.265 | ▲6.187 |
| Price To Earnings Ratio | -7.895 | ▼-7.042 | ▼-5.321 |
| Price To Earnings Growth Ratio | 0.121 | ▲0.119 | ▲0.180 |
| Forward Price To Earnings Growth Ratio | 0.121 | ▲0.119 | ▲0.180 |
| Price To Earnings Diluted Ratio | -7.895 | ▼-7.042 | ▼-5.494 |
| Price To Earnings Diluted Growth Ratio | 0.121 | ▲0.119 | ▲0.182 |
| Price To Book Ratio | 3.742 | ▲2.179 | ▲2.165 |
| Price To Sales Ratio | 0.000 | ▼-2.948 | ▼-23.220 |
| Price To Free Cash Flow Ratio | -9.251 | ▼-7.716 | ▼-20.154 |
| Price To Operating Cash Flow Ratio | -9.262 | ▼-7.725 | ▼-18.180 |
| Debt To Assets Ratio | 0.018 | ▲0.008 | ▲0.007 |
| Debt To Equity Ratio | 0.019 | ▲0.007 | ▲0.008 |
| Debt To Capital Ratio | 0.019 | ▲0.007 | ▲0.007 |
| Long Term Debt To Capital Ratio | 0.015 | ▲0.015 | ▲0.012 |
| Financial Leverage Ratio | 1.090 | ▼-0.086 | ▲0.308 |
| Working Capital Turnover Ratio | 0.000 | ▼-0.321 | ▼-0.297 |
| Operating Cash Flow Ratio | -5.436 | ▲0.465 | ▼-1.566 |
| Operating Cash Flow Sales Ratio | 0.000 | ▲1.919 | ▲1.996 |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | ▲0.000 | ▲0.018 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -20.706 | ▲63.922 | ▲5.529 |
| Capital Expenditure Coverage Ratio | -893.790 | ▲174.025 | ▼-446.769 |
| Dividend Paid And Capex Coverage Ratio | -893.790 | ▲174.025 | ▼-446.769 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -6.393 | ▼-5.767 | ▼-3.262 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.14B | $257.6M | $989.7M | $2.46B | $1.05B | |
| Enterprise value | $921.7M | $182.2M | $823.7M | $2.40B | $995.4M | |
| EV / Sales | 0.00x | 2.08x | 2.16x | 108.02x | 0.00x | |
| EV / Op. cash flow | -7.47x | -1.09x | 69.11x | -13.35x | -13.31x | |
| EV / Free cash flow | -7.46x | -1.09x | 77.14x | -13.17x | -13.24x | |
| EV / EBITDA | -6.39x | -0.63x | 14.87x | -12.18x | -11.33x | |
| Net debt / EBITDA | 1.53x | 0.26x | -3.00x | 0.28x | 0.57x | |
| Current ratio | 14.27x | 6.67x | 5.66x | 8.20x | 6.03x | |
| Income quality | 0.85x | 0.56x | 0.24x | 0.91x | 0.85x | |
| Graham number | — | — | $10 | — | — | |
| Graham net-net | $3 | $2 | $5 | $5 | -$3 | |
| Tax burden | 100.0% | 99.9% | 90.7% | 100.4% | 100.0% | |
| Interest burden | 100.0% | 103.5% | 100.0% | 100.0% | 100.0% | |
| Working capital | $301.0M | $161.0M | $382.6M | $335.5M | $87.6M | |
| Invested capital | $306.5M | $163.8M | $389.0M | $343.7M | $88.0M | |
| Return on assets | -43.5% | -155.8% | 9.5% | -50.7% | -83.3% | |
| Operating ROA | -58.3% | -88.5% | 8.5% | -81.0% | -138.1% | |
| Return on tangible assets | -43.5% | -155.8% | 9.5% | -50.7% | -83.3% | |
| Return on equity | -47.4% | -183.1% | 11.4% | -58.2% | 58.2% | |
| Return on invested capital | -49.3% | -188.5% | 8.0% | -58.0% | -93.7% | |
| Return on capital employed | -49.5% | -190.5% | 8.9% | -58.4% | -93.7% | |
| Earnings yield | -12.7% | -117.1% | 5.0% | -8.1% | -8.4% | |
| Free cash flow yield | -10.8% | -65.1% | 1.1% | -7.4% | -7.2% | |
| Capex / Op. cash flow | -0.1% | -0.1% | 10.4% | -1.4% | -0.5% | |
| Capex / Depreciation | 26.3% | 17.4% | 114.1% | 518.7% | 678.8% | |
| Capex / Sales | 0.0% | 0.2% | 0.3% | 11.4% | 0.0% | |
| SG&A / Sales | 0.0% | 130.9% | 49.5% | 571.9% | 0.0% | |
| R&D / Sales | 0.0% | 119.1% | 33.7% | 420.4% | 0.0% | |
| Stock comp / Sales | 0.0% | 37.8% | 9.8% | 97.7% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 2d | 38d | 251d | 0d | |
| Days payables outstanding | 2447d | 25d | 317d | 763d | 0d | |
| Operating cycle | 0d | 2d | 588d | 1443d | 0d | |
| Cash conversion cycle | -2447d | -24d | 272d | 680d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-06 Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in PBH at ObesityWeek® 2026 Annual Meeting.
- 2026-10-04 Dyadic International (NASDAQ:DYAI) & Amylyx Pharmaceuticals (NASDAQ:AMLX) Critical Review Amylyx Pharmaceuticals (NASDAQ: AMLX - Get Free Report) and Dyadic International (NASDAQ: DYAI - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, institutional ownership and profitability. Volatility and Risk Amylyx Pharmaceuticals has a beta
- 2026-10-03 Amylyx''s Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment Amylyx Pharmaceuticals NASDAQ: AMLX said its Phase III trial of avexitide in post-bariatric hypoglycemia, or PBH, met its primary endpoint and all secondary endpoints, positioning the company to submit a New Drug Application to the U.S. Food and Drug Administration before year-end.
- 2026-10-01 10 Stocks With Massive Short Squeeze Potential Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into Q4. Where are short sellers putting their money?
- 2026-09-16 Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2026-09-10 Better Healthcare ETF: Vanguard''s VHT vs. State Street''s Pharmaceuticals-Focused XPH Vanguard''s broader healthcare portfolio charges less and yields more, but State Street''s pharma-focused fund has delivered stronger recent gains despite higher volatility.
- 2026-09-10 Which Healthcare ETF Is the Better Buy: Fidelity''s Broad FHLC or State Street''s Pharma-Focused XPH? FHLC captures the whole healthcare opportunity at rock-bottom cost. XPH narrows the bet to pharmaceuticals and charges significantly more for it.
- 2026-09-01 Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%? Amylyx Pharmaceuticals raised $500 million to strengthen its balance sheet. A potential 2027 drug launch could provide the company''s next catalyst.
- 2026-08-29 BlackRock Inc. Acquires New Stake in Amylyx Pharmaceuticals, Inc. $AMLX BlackRock Inc. bought a new position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 8,827,085 shares of the company''s stock, valued at approximately $158,534,000. BlackRock Inc. owned approximately 7.94% of Amylyx Pharmaceuticals as
- 2026-08-29 BlackRock Inc. Acquires New Stake in Amylyx Pharmaceuticals, Inc. $AMLX BlackRock Inc. bought a new position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 8,827,085 shares of the company''s stock, valued at approximately $158,534,000. BlackRock Inc. owned approximately 7.94% of Amylyx Pharmaceuticals as